A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07182149 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

HNSCC
ESCC
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
GEJ Adenocarcinoma
Ovarian Cancer
NSCLC
Cervical Cancer
Endometrial Cancer
Triple Negative Breast Cancer (TNBC)

Interventions

DRUG: NRM-823

Sponsor

Normunity AccelCo, Inc.